Reni Benjamin
Stock Analyst at Citizens
(1.38)
# 3,655
Out of 5,133 analysts
161
Total ratings
37.96%
Success rate
-13.03%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.64 | +204.88% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.58 | +79.21% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $6.49 | +84.90% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $73.28 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.35 | +470.45% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.31 | +224.46% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $103.43 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $8.29 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.57 | +600.04% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.97 | +103.05% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.24 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.87 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $17.70 | -43.50% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.70 | +6.38% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $9.21 | +204.02% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $7.20 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $16.81 | +137.95% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.35 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.24 | +78.57% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.63 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.48 | -15.61% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $45.20 | +32.74% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.20 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $199.55 | +57.86% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $85.41 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $259.87 | +1.97% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.02 | +322.89% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $15.05 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.75 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $27.87 | -56.94% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.83 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $1.64
Upside: +204.88%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.58
Upside: +79.21%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $6.49
Upside: +84.90%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $73.28
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.35
Upside: +470.45%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.31
Upside: +224.46%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $103.43
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.29
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.57
Upside: +600.04%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.97
Upside: +103.05%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.24
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.87
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $17.70
Upside: -43.50%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.70
Upside: +6.38%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $9.21
Upside: +204.02%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.20
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $16.81
Upside: +137.95%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.35
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.24
Upside: +78.57%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $10.63
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.48
Upside: -15.61%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $45.20
Upside: +32.74%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.20
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $199.55
Upside: +57.86%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $85.41
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $259.87
Upside: +1.97%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.02
Upside: +322.89%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $15.05
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $27.87
Upside: -56.94%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $19.83
Upside: -